HRI1 Antibody

What is HRI/EIF2AK1 and why is it a significant research target?

HRI (Heme-Regulated Inhibitor) is an alias name for the human gene EIF2AK1 (eukaryotic translation initiation factor 2 alpha kinase 1). The 630-amino acid protein belongs to the Protein kinase superfamily, Ser/Thr protein kinase family, and more specifically to the GCN2 subfamily. Its cellular localization is predominantly cytoplasmic, where it plays crucial roles in regulating protein synthesis under various stress conditions. As a kinase that phosphorylates the alpha subunit of eukaryotic translation initiation factor 2 (eIF2α), HRI represents an important research target for understanding translational control mechanisms, cellular stress responses, and heme-dependent regulation pathways .

What applications are most suitable for HRI antibodies in research?

HRI antibodies are versatile tools employed across multiple experimental applications. According to commercially available antibody data, the most common applications include:

These antibodies have demonstrated reactivity primarily with human (Hu) samples, though some products also show cross-reactivity with mouse (Ms) and monkey (Mk) samples . When selecting applications, researchers should consider the specific epitope recognized by the antibody and whether the detection method is compatible with the experimental conditions that preserve this epitope.

How should researchers evaluate antibody specificity before experimental use?

Antibody specificity assessment is critical for reliable experimental outcomes. A methodical approach involves:

• Sequence analysis: Confirm that the immunogen sequence used to generate the antibody corresponds to unique regions of HRI/EIF2AK1.

• Positive controls: Include lysates or samples with known HRI expression.

• Negative controls: Use knockout/knockdown models or tissues known to lack HRI expression.

• Competing peptide assays: Pre-incubate the antibody with the immunizing peptide to demonstrate binding specificity.

• Multiple antibody validation: Compare results using antibodies targeting different epitopes of HRI (N-terminal, Center, C-terminal) .

What are the optimal conditions for using HRI antibodies in different applications?

Optimizing experimental conditions is essential for maximizing signal-to-noise ratio when using HRI antibodies:

For Western Blotting:

• Sample preparation: Use RIPA buffer with protease and phosphatase inhibitors

• Protein loading: 20-50 μg per lane

• Blocking: 5% non-fat milk or BSA in TBST (1-2 hours)

• Primary antibody incubation: Overnight at 4°C at dilutions between 1:500-1:2000

• Detection method: HRP-conjugated secondary antibodies with ECL detection

For Immunohistochemistry:

• Fixation: 4% paraformaldehyde or formalin

• Antigen retrieval: Citrate buffer (pH 6.0) heat-induced epitope retrieval

• Blocking: 5-10% normal serum from the species of the secondary antibody

• Primary antibody incubation: 1:100-1:500 dilution overnight at 4°C

• Detection system: ABC or polymer-based detection systems

For ELISA:

• Coating concentration: 1-5 μg/ml of capture antibody

• Blocking: 1-3% BSA in PBS

• Sample dilution: Perform serial dilutions to ensure readings within the linear range

• Detection antibody: Use 1:1000-1:5000 dilution

How can machine learning approaches enhance antibody selection for targets like HRI?

Machine learning (ML) has emerged as a powerful tool for antibody engineering and selection, particularly for challenging targets. A methodological framework includes:

• Data collection and analysis: Compile antibody repertoire data from immunized animals or human sources. For HRI antibodies, sequence information from successful binders can be used to train ML models .

• Model training: Develop supervised ML models that correlate antibody sequences with binding properties. Recent studies demonstrate that models like Gaussian Process with Matérn kernel (GP_Matern) can achieve remarkable accuracy in predicting antibody affinity, even with limited dataset sizes .

• Affinity prediction: Use trained models to predict binding affinities of variant antibodies. This approach reduces the need for extensive experimental screening .

• In silico design: Generate and evaluate synthetic antibody variants computationally before experimental validation. In one study, seven out of eight in silico-designed antibody variants exhibited the predicted affinities when tested experimentally .

• Experimental validation: Verify computationally designed antibodies using techniques like biolayer interferometry (BLI) to measure binding kinetics and affinities (association rate, dissociation rate, and equilibrium dissociation constant) .

What are effective strategies for measuring HRI antibody affinity and specificity?

Precise measurement of antibody-antigen interactions provides critical information for research applications. Methodological approaches include:

• Biolayer Interferometry (BLI): This label-free technique measures binding kinetics in real-time. For HRI antibodies, immobilize either the antibody or the antigen on biosensor tips and measure association (ka), dissociation (kd) rates, and calculate the equilibrium dissociation constant (KD). Quality assessment should include coefficient of determination (R² value) calculations, with values above 0.95 indicating reliable measurements .

• Surface Plasmon Resonance (SPR): Similar to BLI, SPR provides real-time binding data. The methodology involves immobilizing either antibody or antigen on a sensor chip and flowing the binding partner over the surface.

• Isothermal Titration Calorimetry (ITC): This technique measures the heat changes during binding, providing thermodynamic parameters in addition to affinity.

• Competitive ELISA: This approach allows relative comparison of antibody affinities by measuring IC50 values.

• Flow Cytometry: For cell-surface targets, flow cytometry with titration series can provide EC50 values that correlate with antibody affinity.

What are common challenges when working with HRI antibodies and how can they be addressed?

Researchers frequently encounter technical challenges when working with antibodies against intracellular targets like HRI:

Challenge 1: Non-specific binding

• Solution: Optimize blocking conditions using 5% BSA instead of milk for phospho-specific applications

• Methodology: Increase washing steps (5× 5 minutes) with TBST containing 0.1-0.3% Tween-20

• Control strategy: Include isotype controls and pre-immune serum controls

Challenge 2: Poor signal detection

• Solution: Optimize antibody concentration through titration experiments

• Methodology: Enhance antigen retrieval methods for fixed samples

• Validation approach: Verify protein expression levels using orthogonal methods

Challenge 3: Inconsistent results

• Solution: Standardize lysate preparation protocols

• Methodology: Document lot-to-lot variations in antibody performance

• Quality control: Include positive control samples with known HRI expression levels

What essential controls should be included when using HRI antibodies?

Robust experimental design requires appropriate controls:

• Positive controls: Include samples with verified HRI expression (e.g., cell lines known to express HRI)

• Negative controls:

  • Samples lacking HRI expression

  • Competitive blocking with immunizing peptide

  • Isotype control antibodies

• Loading controls: For western blots, include housekeeping proteins (β-actin, GAPDH)

• Secondary antibody-only controls: To assess non-specific binding of detection antibodies

• Phosphorylation-specific controls: When studying HRI activation, include samples treated with phosphatase

How can researchers effectively use multiple HRI antibodies for comprehensive protein characterization?

A multi-antibody approach enhances confidence in experimental results and provides complementary data:

• Epitope mapping strategy: Utilize antibodies targeting different regions of HRI, such as N-terminal, Center, and C-terminal domains . This approach helps confirm protein identity and can reveal isoform-specific expression patterns.

• Functional domain analysis: Select antibodies that recognize specific functional domains of HRI, such as the kinase domain, to correlate with functional assays.

• Post-translational modification detection: Combine pan-HRI antibodies with modification-specific antibodies (phospho-specific, ubiquitin-specific) to assess regulatory mechanisms.

• Combinatorial application approach:

What considerations are important when studying HRI in complex biological systems?

When investigating HRI in complex samples such as tissue lysates or patient specimens:

• Sample preparation optimization: Different extraction methods may be required to maintain HRI conformational integrity. Test multiple lysis buffers (RIPA, NP-40, Triton X-100) to determine optimal conditions.

• Context-dependent expression analysis: HRI expression and activity can vary significantly across tissue types and under different stress conditions. Consider relevant physiological contexts such as:

  • Heme availability

  • Oxidative stress conditions

  • Integrated stress response activation

• Interaction studies methodology: When investigating HRI interactions with other proteins:

  • Use chemical crosslinking before immunoprecipitation to capture transient interactions

  • Consider native PAGE conditions that preserve protein complexes

  • Employ proximity ligation assays for in situ interaction detection

How can combinatorial antibody approaches enhance detection specificity?

Drawing from strategies used in other systems, such as SARS-CoV antibody research, combinatorial approaches can significantly improve specificity and functional outcomes:

• Antibody cocktails: Utilizing multiple HRI antibodies targeting different epitopes can enhance detection sensitivity and specificity. Research on other targets has shown that combinations of antibodies against different domains (e.g., equivalent to S1 and S2 domains in viral proteins) provide improved detection across variants .

• Methodological implementation: When designing multiplex detection systems:

  • Use different reporter systems for each antibody

  • Optimize antibody ratios to prevent competition

  • Validate the combined approach against individual antibodies

• Synergistic neutralization: In functional studies, combining antibodies targeting different functional domains can achieve synergistic inhibition of protein activity. Data from viral research demonstrates that such combinations provide broader neutralization capabilities and reduce the likelihood of escape variants .

What are the methodological considerations for monitoring HRI in dynamic cellular processes?

To capture the dynamic regulation of HRI in cellular systems:

• Live-cell imaging approaches: Develop methods combining HRI antibody fragments with cell-penetrating peptides for intracellular tracking.

• Time-resolved analysis: Implement pulse-chase experiments with systematic sampling to monitor HRI expression, localization, and modification changes over time.

• Single-cell analysis techniques: Adapt antibody-based detection methods for flow cytometry or mass cytometry (CyTOF) to assess HRI heterogeneity across cell populations.

• Proximity-based detection: Employ split reporter systems or FRET-based approaches to monitor HRI interactions with binding partners in real-time.

• Automation and high-throughput screening: Develop automated immunoassay workflows to facilitate large-scale screening of HRI modulators or stress response activators.